Zila divests Zilactin
This article was originally published in The Tan Sheet
Phoenix-based company sells its Zilactin brand of OTC lip and oral care products to Columbus, Ind.-based Blairex Laboratories for $10.3 mil. "plus agreed upon working capital adjustments," Zila announces June 27. The line includes Zilactin and Zilactin-B (benzocaine), both marketed for the treatment of cold sores, canker sores and fever blisters. The divestiture of the "non-strategic asset" is in line with Zila's plan to focus on "preventive healthcare technologies" such as its Ester-C and Ester-E supplement lines, according to the firm...
You may also be interested in...
While endocrine-disrupting evidence was inconclusive, the Scientific Committee on Consumer Safety recommends more conservative limits on use of homosalate, octocrylene and benzophenone-3 in cosmetic products compared with current requirements under the European Cosmetics Product Regulation.
The risk of inadvertently growing SARS-CoV-2 virus in cell and gene therapies and possibly infecting patients and workers should be assessed and mitigated, the agency advises.
Move was meant to preempt others’ efforts to secure the next six months of Regeneron’s COVID-19 antibody therapeutic.